Status:
COMPLETED
Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID-3)
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Pseudomonas Aeruginosa
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
P. aeruginosa is an opportunistic bacterium known to be responsible for numerous healthcare-associated infections, particularly in intensive care units (ICU). The frequency of these infections seems t...
Eligibility Criteria
Inclusion
- Adult patients hospitalized for at least 48 h in an intensive care unit (ICU) at CHRU-Nancy for acute respiratory distress syndrome due to COVID-19.
- Patients hospitalized from 1st March 2020 to 31st May 2021.
- Patient developed an hospital-acquired infection caused by P. aeruginosa during their ICU stay.
Exclusion
- Patients \<18 years old.
- Patient without COVID-19 at the ICU admission.
- Patients with P. aeruginosa isolated \<48 hours following ICU admission.
- Patients who did not want to be included in the study.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 20 2024
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT06141837
Start Date
December 1 2023
End Date
April 20 2024
Last Update
May 7 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.